Medical device maker Dexcom (DXCM -13.3%) takes a hit after its Q3 misses across the board, hurt...
Medical device maker Dexcom (DXCM -13.3%) takes a hit after its Q3 misses across the board, hurt by lagging international sales and higher operational costs. The company says the declining sales trend is likely to continue, and lowers FY11 guidance. It now expects revenue in the range of $62.5M - $67.5M, down from prior estimates of $67.5- $72.5M. Separately, Morgan Keegan cuts the shares to Market Perform off the results.
From other sites
at CNBC.com (Jan 15, 2015)
at CNBC.com (Sep 4, 2014)
at CNBC.com (Aug 25, 2014)
at CNBC.com (Jul 30, 2014)
at CNBC.com (Apr 15, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs